Immunosuppressive therapy with rituximab in common variable immunodeficiency
A Pecoraro, L Crescenzi, MR Galdiero… - Clinical and Molecular …, 2019 - Springer
Common variable immunodeficiency (CVID) is the most frequent symptomatic primary
antibody deficiency in adulthood and is characterized by the marked reduction of IgG and …
antibody deficiency in adulthood and is characterized by the marked reduction of IgG and …
Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts
M Flanagan, I Pathak, Q Gan, L Winter, R Emnet… - Stem Cell Research & …, 2021 - Springer
Abstract Background Mucopolysaccharidosis IVA (Morquio A syndrome) is a lysosomal
storage disease caused by the deficiency of enzyme N-acetylgalactosamine-6-sulfate …
storage disease caused by the deficiency of enzyme N-acetylgalactosamine-6-sulfate …
Cotrimoxazole for the Infection Prevention in Glomerulonephritis Treated with Rituximab
Y Chen, Y Zha, A Hu, X YU, B Ma, J Han, X Xue, R Lu… - papers.ssrn.com
Objectives: We aimed to explore the safety and efficacy of cotrimoxazole for infection
prevention in glomerulonephritis treated with rituximab.. Study Design and Methods: This …
prevention in glomerulonephritis treated with rituximab.. Study Design and Methods: This …
Resistance to Monoclonal Antibody Therapeutics in Lymphoma
MJ Barth, SC Goldman - Resistance to Targeted Therapies in Lymphomas, 2019 - Springer
With the long history of rituximab use in CD20 positive lymphomas and the recent approval
of brentuximab vedotin for the treatment of Hodgkin lymphoma and anaplastic large cell …
of brentuximab vedotin for the treatment of Hodgkin lymphoma and anaplastic large cell …